^
    10d
    RELATIVITY-069: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=5, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=68 --> 5 | Trial completion date: Jul 2028 --> Dec 2025 | Trial primary completion date: Jul 2028 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    15d
    Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (clinicaltrials.gov)
    P2, N=494, Recruiting, Melanoma Institute Australia | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    22d
    STELLAR-002: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=1314, Recruiting, Exelixis | Active, not recruiting --> Recruiting
    Enrollment open
    |
    FH (Fumarate Hydratase)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • zanzalintinib (XL092)
    23d
    CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=27, Completed, Jose Lutzky, MD | Active, not recruiting --> Completed
    Trial completion
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    29d
    A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    1m
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    1m
    Abscopal Effect Induced by LAG-3/PD-1 Inhibition and Radiation Therapy in Metastatic Acral Melanoma: A Case Report. (PubMed, Case Rep Oncol)
    Relatlimab, a LAG-3 inhibitor, in combination with nivolumab, a PD-1 inhibitor, has recently emerged as a dual ICI strategy targeting T-cell exhaustion. This case illustrates the potential synergistic effect of sequential LAG-3/PD-1 inhibition followed by radiation therapy in eliciting systemic immune activation in AM. It represents the first reported instance of an abscopal effect associated with relatlimab-based immunotherapy, suggesting that strategic sequencing of immunotherapy and radiation may be critical in overcoming immune resistance in this challenging melanoma subtype.
    Journal
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    1m
    NOBLE: Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, National Health Research Institutes, Taiwan
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • cisplatin • gemcitabine • relatlimab (BMS-986016)
    1m
    Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in cancer patients. (PubMed, J Cardiovasc Pharmacol)
    HFCs were exposed for 48h to Nivolumab plus Relatlimab, Ipilimumab, or Atezolizumab, either alone or in triplet combinations. Our findings demonstrate that ICI triplets elicit potent immune activation against cardiomyocytes, providing the first preclinical evidence of direct cardiotoxic potential in this setting. These results highlight the need for enhanced clinical surveillance and cardio-oncology monitoring in patients receiving triple ICI combinations, as these regimens expand in clinical practice.
    Journal • Checkpoint inhibition
    |
    GZMB (Granzyme B) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    2ms
    RELATIVITY-106: A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (clinicaltrials.gov)
    P1/2, N=83, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=162 --> 83 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial primary completion date
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • relatlimab (BMS-986016)
    2ms
    GIANT: Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (clinicaltrials.gov)
    P2, N=92, Recruiting, Duke University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    2ms
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov)
    P2, N=20, Completed, Dan Zandberg | Active, not recruiting --> Completed
    Trial completion
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)